Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (DE:TG1N)
STUTTGART:TG1N
TG1N Stock Chart & Stats
€7.05
-€0.01(-0.52%)
At close: 4:00 PM EST
€7.05
-€0.01(-0.52%)
Day’s Range― - ―
52-Week Range€0.70 - €7.05
Previous CloseN/A
Volume0.00
Average Volume (3M)189.00
Market Cap
$250.50M
Enterprise Value€480.76M
Total Cash (Recent Filing)$14.76M
Total Debt (Recent Filing)$177.68M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding36,406,906
10 Day Avg. Volume50
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.39
Price to Sales (P/S)12.93
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.92
Enterprise Value/Revenue95.12
Enterprise Value/Gross Profit135.01
Enterprise Value/Ebitda-15.83
Forecast
1Y Price Target
$10.15Price Target Upside43.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataPhase 2 results showed AP-SA02 added to standard antibiotics produced better clinical outcomes with no evidence of relapse and a favorable safety profile, supporting potential use as a frontline adjunct in complicated Staphylococcus aureus bloodstream infections.
Manufacturing CapacityCommissioning of a dedicated cGMP phage manufacturing facility with successful initial production runs demonstrates operational readiness to supply pivotal trials and potential commercial demand.
RegulatoryFDA provided written feedback supporting progression of AP-SA02 into a superiority-based Phase 3 study, creating a clearer regulatory pathway and signaling meaningful agency endorsement.
Bears Say
Execution RiskInitiation of the pivotal trial depends on completion of regulatory, manufacturing, and operational milestones, creating execution risk if any element is delayed or not met.
Funding RiskLimited cash resources increase the likelihood that additional funding will be required to advance pivotal and follow-on trials, creating dilution risk and potential delays to development plans.
Research ObjectivityThe covering firm’s business relationships with issuers may create conflicts that could affect the perceived objectivity of analyst reports and investor confidence.
Armata Pharmaceuticals News
TG1N FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was €0.70 and its highest was €7.05 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $250.50M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 24 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -€0.626 earnings per share for the quarter, missing the consensus estimate of -€0.355 by -€0.271.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.24.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -€0.626 in its last earnings report, missing expectations of -€0.355. Following the earnings report the stock price went down -0.87%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:TG1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
TG1N Stock 12 Month Forecast
Average Price Target
€10.15
▲(43.93% Upside)
Technical Analysis
Options Prices
Currently, No data available
---